{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:59:50Z","timestamp":1778770790145,"version":"3.51.4"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,6]]},"DOI":"10.7759\/cureus.44805","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T05:56:20Z","timestamp":1694066180000},"source":"Crossref","is-referenced-by-count":2,"title":["The First Sign of Recurrent Angioimmunoblastic T-Cell Lymphoma: A Cutaneous Presentation"],"prefix":"10.7759","author":[{"given":"Guy","family":"Charest","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"McBride","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda K","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitch","family":"Manway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J","family":"DiCaudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqab090","article-title":"How I diagnose angioimmunoblastic T-cell lymphoma","volume":"156","author":"Xie Y","year":"2021","unstructured":"Xie Y, Jaffe ES. How I diagnose angioimmunoblastic T-cell lymphoma. Am J Clin Pathol. 2021, 156:1-14. 10.1093\/ajcp\/aqab090","journal-title":"Am J Clin Pathol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010387","article-title":"Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the International T-cell Project","volume":"138","author":"Advani RH","year":"2021","unstructured":"Advani RH, Skrypets T, Civallero M, et al.. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the International T-cell Project. Blood. 2021, 138:213-20. 10.1182\/blood.2020010387","journal-title":"Blood"},{"key":"ref3","article-title":"Other lymphoproliferative and myeloproliferative diseases","author":"Winfield HL","year":"2018","unstructured":"Winfield HL, Smoller BR. Other lymphoproliferative and myeloproliferative diseases. Dermatology, Third Edition. Bolognia JL, Jorizzo JL, Schaffer JV (ed): Elsevier Health Sciences, Philadelphia, PA; 2018. 2157:2037-48."},{"key":"ref4","article-title":"Cutaneous T-cell lymphoma, NK-cell lymphoma and myeloid leukemia","author":"Elston D","year":"2018","unstructured":"Elston D, Ferringer T, Ko C, Peckham S, High WA, DiCaudo DJ. Cutaneous T-cell lymphoma, NK-cell lymphoma and myeloid leukemia. Dermatopathology, Third Edition. Elsevier Health Sciences, Philadelphia, PA; 2018. 917."},{"key":"ref5","article-title":"Peripheral T-Cell Lymphoma","author":"Rangoonwala HI","year":"2023","unstructured":"Rangoonwala HI, Cascella M. Peripheral T-Cell Lymphoma. StatPearls [Internet], StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.05.030","article-title":"Evaluation of cutaneous angioimmunoblastic T-cell lymphoma","volume":"65","author":"Balaraman B","year":"2011","unstructured":"Balaraman B, Conley JA, Sheinbein DM. Evaluation of cutaneous angioimmunoblastic T-cell lymphoma. J Am Acad Dermatol. 2011, 65:855-62. 10.1016\/j.jaad.2010.05.030","journal-title":"J Am Acad Dermatol"},{"key":"ref7","article-title":"Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies","volume":"6","author":"Alizadeh AA","year":"2008","unstructured":"Alizadeh AA, Advani RH. Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies. Clin Adv Hematol Oncol. 2008, 6:899-909.","journal-title":"Clin Adv Hematol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059281","article-title":"Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group","volume":"6","author":"Siegert W","year":"1995","unstructured":"Siegert W, Nerl C, Agthe A, et al.. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann Oncol. 1995, 6:659-64. 10.1093\/oxfordjournals.annonc.a059281","journal-title":"Ann Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/185372-the-first-sign-of-recurrent-angioimmunoblastic-t-cell-lymphoma-a-cutaneous-presentation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:06:12Z","timestamp":1707509172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/185372-the-first-sign-of-recurrent-angioimmunoblastic-t-cell-lymphoma-a-cutaneous-presentation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,6]]},"references-count":8,"URL":"https:\/\/doi.org\/10.7759\/cureus.44805","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,6]]}}}